Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.44 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrantoin SCHEMBL29582305 | 1.00 | TSHR (0.54) | TSHRTDP1AKR1B1ATMALDH1A1 | |
| SCHEMBL12199729 | 0.93 | TSHR (0.57) | TSHRTDP1AKR1B1ALDH1A1CRBN | |
| SCHEMBL409009 | 0.89 | TSHR (0.47) | TSHRTDP1AKR1B1ALDH1A1CRBN | |
| SCHEMBL13055196 | 0.80 | CALCRL (0.43) | TSHRTDP1AKR1B1ALDH1A1CALCRL | |
| SCHEMBL7924805 | 0.79 | TSHR (0.41) | TSHRTDP1AKR1B1CALCRL | |
| SCHEMBL1715181 | 0.79 | CALCRL (0.43) | TSHRTDP1AKR1B1CALCRLMAPT | |
| SCHEMBL14536414 | 0.79 | CALCRL (0.43) | TSHRTDP1AKR1B1CALCRLMAPT | |
| SCHEMBL31232518 | 0.79 | OPRM1 (0.42) | TSHRTDP1ALDH1A1CRBNCALCRL | |
| SCHEMBL1715310 | 0.79 | CALCRL (0.43) | TSHRTDP1AKR1B1CALCRL | |
| SCHEMBL1714787 | 0.79 | TDP1 (0.41) | TSHRTDP1AKR1B1CALCRLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 955 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| CN-101484152-A | Therapeutic combination for painful medical conditions | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-07-15 | — | — | CN | claimed |
| EP-2026788-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007141018-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2007-12-13 | — | — | WO | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | SRZ PROPERTIES, INC. (US) | 2007-02-22 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4160818-A | Fluorimetric immunoassay for diphenylhydantoin | TECHNICON INSTRUMENTS CORPORATION (US) | 1979-07-10 | — | — | US | claimed |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12370191-B2 | Treatment and prevention of sleep disorders | PURDUE PHARMA L.P. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L.P. (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2025085818-A1 | SUNOBINOP FOR USE IN METHOD OF TREATING ALCOHOL USE DISORDER | PURDUE PHARMA L.P. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-4680284-A | RENNIN INHIBITORS, HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0189203-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1986-07-30 | — | — | EP | disclosed |
| US-4160818-A | Fluorimetric immunoassay for diphenylhydantoin | TECHNICON INSTRUMENTS CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | GRIN2B, GRIN2A, GRIN3A | TSHR 2950/4885TDP1 2854/4885AKR1B1 2361/4885 |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | CRY1, PER2, SLC6A1 | TSHR 2602/4885TDP1 852/4885AKR1B1 2091/4885 |
| US-12370191-B2 | Treatment and prevention of sleep disorders | HCRTR1, HCRTR2, MTNR1A | TSHR 2270/4885TDP1 1050/4885AKR1B1 2035/4885 |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | HCRTR2, HCRTR1, CRY1 | TSHR 3068/4885TDP1 2178/4885AKR1B1 3053/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | TSHR 1947/4885TDP1 1017/4885AKR1B1 76/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | TSHR 2634/4885TDP1 2352/4885AKR1B1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.